R. Mirimanoff

Publications144
h-index39
Citations19,789
Highly Influential Citations796
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • R. Stupp
  • 427 Publications, 45,389 Citations
  • M. Ozsahin
  • 347 Publications, 8,409 Citations
  • M. J. van den Bent
  • 336 Publications, 37,892 Citations
  • F. Buchegger
  • 194 Publications, 5,683 Citations
  • Publications
  • Influence
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
BACKGROUND Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal. The current standard of care for newly diagnosed glioblastoma is surgical resection to the extent… Expand
  • 8,771
  • 447
  • Open Access
MGMT gene silencing and benefit from temozolomide in glioblastoma.
BACKGROUND Epigenetic silencing of the MGMT (O6-methylguanine-DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in… Expand
  • 3,377
  • 150
  • Open Access
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
PURPOSE Temozolomide is a novel oral alkylating agent with demonstrated efficacy as second-line therapy for patients with recurrent anaplastic astrocytoma and glioblastoma multiforme (GBM). This… Expand
  • 756
  • 23
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
BACKGROUND We conducted a randomized, prospective trial comparing external irradiation with external irradiation plus goserelin (an agonist analogue of gonadotropin-releasing hormone that reduces… Expand
  • 1,080
  • 21
  • Open Access
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
BACKGROUND A randomised trial published by the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group (trial… Expand
  • 424
  • 19
  • Open Access
Meningioma: analysis of recurrence and progression following neurosurgical resection.
The rates of survival, tumor recurrence, and tumor progression were analyzed in 225 patients with meningioma who underwent surgery as the only treatment modality between 1962 and 1980. Patients were… Expand
  • 884
  • 16
  • Open Access
CD4 and CD8 T-Lymphocyte Apoptosis Can Predict Radiation-Induced Late Toxicity: A Prospective Study in 399 Patients
Purpose: Predicting late effects in patients treated with radiation therapy by assessing in vitro radiation-induced CD4 and CD8 T-lymphocyte apoptosis can be useful in individualizing treatment.… Expand
  • 187
  • 15
  • Open Access
Clinical implications of the p53 tumor-suppressor gene.
  • 275
  • 8
Health-related quality of life in patients with glioblastoma: a randomised controlled trial.
BACKGROUND A randomised controlled trial of radiotherapy alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma showed that survival was higher for… Expand
  • 260
  • 7
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Treatment of malignant glioma requires a multidisciplinary team. Treatment includes surgery, radiotherapy, and chemotherapy. Recently developed agents have demonstrated activity against recurrent… Expand
  • 361
  • 6